Flindokalner

Summary

Flindokalner (CHEMBL266510) is a phase-3 clinical-stage small molecule targeting KCNMA1, KCNQ2, and KCNQ4.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 4 (KCNMA1, KCNQ2, KCNQ4…)
• Clinical trials: 2
• Chemistry: 359.7 Da · C16H10ClF4NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL266510
Name	Flindokalner
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	214350
Molecular formula	C16H10ClF4NO2
Molecular weight	359.7
InChIKey	ULYONBAOIMCNEH-HNNXBMFYSA-N

SMILES: COC1=C(C=C(C=C1)Cl)[C@]2(C3=C(C=C(C=C3)C(F)(F)F)NC2=O)F

IUPAC name: (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1H-indol-2-one

Also known as: BMS-204352, Flindokalner, Maxipost, FLINDOKALNER, flindokalner

Patent coverage: 35 distinct patent families (74 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 53 (72%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
KCNMA1	KCa1.1		6.5	0.1%	Q12791
KCNQ2	Kv7.2		5	0%	O43526
KCNQ4	Kv7.4		5	0.6%	P56696
KCNQ5	Kv7.5		5.6	1.2%	Q9NR82

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3, Potassium voltage-gated channel subfamily KQT member 5, Potassium voltage-gated channel subfamily KQT member 4, Calcium-activated potassium channel subunit alpha-1.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNMA1	6.46	EC50	350	nM	CHEMBL_ACT_29286031
KCNMA1	6.45	EC50	352	nM	CHEMBL_ACT_12662664
KCNQ5	5.62	EC50	2400	nM	CHEMBL_ACT_12662588
KCNQ4	5.62	EC50	2400	nM	CHEMBL_ACT_12662589
KCNQ3	5.62	EC50	2400	nM	CHEMBL_ACT_12662590
KCNQ2	5.62	EC50	2400	nM	CHEMBL_ACT_12662591

Target pathways

Aggregated over 4 target gene(s): KCNMA1, KCNQ2, KCNQ4, KCNQ5.

Top Reactome pathways

18 total, by targets touching each:

Pathway	Targets	Genes
Neuronal System	4	KCNMA1, KCNQ2, KCNQ4, KCNQ5
Potassium Channels	4	KCNMA1, KCNQ2, KCNQ4, KCNQ5
Voltage gated Potassium channels	3	KCNQ2, KCNQ4, KCNQ5
Sensory processing of sound	2	KCNMA1, KCNQ4
Sensory processing of sound by inner hair cells of the cochlea	2	KCNMA1, KCNQ4
Sensory processing of sound by outer hair cells of the cochlea	2	KCNMA1, KCNQ4
Sensory Perception	2	KCNMA1, KCNQ4
Hemostasis	1	KCNMA1
Developmental Biology	1	KCNQ2
Ca2+ activated K+ channels	1	KCNMA1
L1CAM interactions	1	KCNQ2
Nitric oxide stimulates guanylate cyclase	1	KCNMA1
Platelet homeostasis	1	KCNMA1
cGMP effects	1	KCNMA1
Axon guidance	1	KCNQ2
Interaction between L1 and Ankyrins	1	KCNQ2
Acetylcholine inhibits contraction of outer hair cells	1	KCNMA1
Nervous system development	1	KCNQ2

Dominant GO biological processes

GO term	Targets
potassium ion transport	4
potassium ion transmembrane transport	4
monoatomic ion transport	4
monoatomic ion transmembrane transport	4
transmembrane transport	4
response to hypoxia	1
response to osmotic stress	1
intracellular potassium ion homeostasis	1
response to carbon monoxide	1
vasodilation	1
regulation of membrane potential	1
positive regulation of apoptotic process	1
negative regulation of cell volume	1
response to calcium ion	1
micturition	1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03887325	Not specified	COMPLETED	The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients
NCT05378074	Not specified	UNKNOWN	Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

6 molecules share ≥1 primary target. Top 6 by shared-target count:

Molecule	Source	Status	Shared targets
EZOGABINE	ChEMBL	Phase 4 (approved)	KCNQ2, KCNQ4, KCNQ5
CANNABIDIOL	ChEMBL + PubChem	Phase 4 (approved)	KCNMA1
FLUPIRTINE	ChEMBL	Phase 4 (approved)	KCNQ2
AZETUKALNER	ChEMBL	Phase 3	KCNQ2
Estradiol	PubChem	Approved	KCNMA1
Quinidine	PubChem	Approved	KCNQ2